Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]
News [3579]
Articles [92]
Editorials [5]
Conferences [157]
elearning [19]
Approaches to screening and early detection across Europe
Tit Albreht - Institute of Public Health, Ljubliana, Slovenia
Approaches to screening and early detection across Europe ( Tit Albreht - Institute of Public Health, Ljubliana, Slovenia )
11 Dec 2017
Roche joining forces to forward precision oncology
Ian Walker - Roche Foundation Medicine, Basel, Switzerland
Roche joining forces to forward precision oncology ( Ian Walker - Roche Foundation Medicine, Basel, Switzerland )
11 Dec 2017
Cancer Core Europe
Prof Fabien Calvo - Institute Gustav Roussy, Paris, France
Cancer Core Europe ( Prof Fabien Calvo - Institute Gustav Roussy, Paris, France )
11 Dec 2017
Phase III trial data supports current standard 12-month adjuvant trastuzumab...
Prof Heikki Joensuu - University of Helsinki, Helsinki, Finland
Phase III trial data supports current standard 12-month adjuvant trastuzumab for HER2-positive breast cancer ( Prof Heikki Joensuu - University of Helsinki, Helsinki, Finland )
7 Dec 2017
Immunotherapy shows early promise for patients with trastuzumab-resistant...
Dr Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Immunotherapy shows early promise for patients with trastuzumab-resistant breast cancer ( Dr Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
7 Dec 2017
HER2low invasive breast cancer: Trastuzumab offers no improvement for invasive...
Dr Louis Fehrenbacher - Kaiser Permanente Vallejo Medical Center, California...
HER2low invasive breast cancer: Trastuzumab offers no improvement for invasive disease free survival ( Dr Louis Fehrenbacher - Kaiser Permanente Vallejo Medical Center, California, USA )
7 Dec 2017
Adjuvant trastuzumab did not improve outcomes for patients with HER2-low breast...
Dr Louis Fehrenbacher - Kaiser Permanente Vallejo Medical Center, California...
Adjuvant trastuzumab did not improve outcomes for patients with HER2-low breast cancer ( Dr Louis Fehrenbacher - Kaiser Permanente Vallejo Medical Center, California, USA )
7 Dec 2017
A biological perspective for personalising immunotherapies
Dr Tom Lillie - Head of European Clinical Development, MSD, London, UK
A biological perspective for personalising immunotherapies ( Dr Tom Lillie - Head of European Clinical Development, MSD, London, UK )
6 Dec 2017
Precision Panc, a platform for pancreatic cancer
Prof Andrew Biankin - University of Glasgow, Glasgow, UK
Precision Panc, a platform for pancreatic cancer ( Prof Andrew Biankin - University of Glasgow, Glasgow, UK )
6 Dec 2017
Personalised haematology treatments
Prof Ulrich Jager - Medical University of Vienna, Vienna, Austria
Personalised haematology treatments ( Prof Ulrich Jager - Medical University of Vienna, Vienna, Austria )
6 Dec 2017
The importance of increasing biomarker understanding
Chris Round - Head of EMEA Region, Merck, Darmstadt, Germany
The importance of increasing biomarker understanding ( Chris Round - Head of EMEA Region, Merck, Darmstadt, Germany )
6 Dec 2017
Bevacizumab and colorectal cancer in geriatrics
Thomas Aparicio - Hôpital Saint-Louis, Paris, France
Bevacizumab and colorectal cancer in geriatrics ( Thomas Aparicio - Hôpital Saint-Louis, Paris, France )
16 Nov 2017

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation